Pharmacokinetics and Safety of an Intravitreal Humanized Anti-VEGF-A Monoclonal Antibody (PRO-169), a Biosimilar Candidate to Bevacizumab

BACKGROUND: PRO-169 is a biosimilar candidate to bevacizumab (BEV), a monoclonal antibody (mAb) that inhibits vascular endothelial growth factor-A (VEGF-A) developed for intravitreal use. The current study demonstrates the intraocular pharmacokinetics (PK) of PRO-169 and its safety using New Zealand...

Descripción completa

Detalles Bibliográficos
Autores principales: Muñoz-Villegas, Patricia, Sanchez-Rios, Alejandra, Quinonez-Alvarado, Mayra G, Olvera-Montaño, Oscar, Quintana-Hau, Juan D, Baiza-Duran, Leopoldo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8185251/
https://www.ncbi.nlm.nih.gov/pubmed/34113182
http://dx.doi.org/10.2147/JEP.S308388

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8185251/
https://www.ncbi.nlm.nih.gov/pubmed/34113182
http://dx.doi.org/10.2147/JEP.S308388

Ejemplares similares